To specifically target breast cancer, Rohde et al. developed a chimera, named TRA-miR-126, based on an aptamer for transferrin receptor (TRA), for use as a delivery tool for miR-126, an oncosuppressor miRNA involved in tumor growth, tumor angiogenesis, and metastasis [56]. The gene discussed is TFRC; the disease is neoplasm.